Aller au contenu
Trouver un autre spécialiste

Simon Couillard

Professeur, Faculté de médecine et des sciences de la santé
FMSS Département de médecine

Présentation

Sujet de recherche

Asthma, Cell Signaling and Infectious and Immune Diseases, Chronic Obstructive Pulmonary Disease, Immune Mediators: Cytokines and Chemokines

Disciplines de recherche

Immunology, Pneumology

Mots-clés

Asthma, Airway inflammation, Clinical prediction models, Chronic obstructive pulmonary disease (COPD)

Intérêts de recherche

Asthma of all severities: biomarkers, phenotypes, personalised medicine - specifically for clinical problems encountered by primary care providers. Airway inflammation: epithelial response, eosinophil biology. Clinical prediction modelling: prognostic modelling and prevention of asthma attacks. Chronic obstructive pulmonary disease (COPD): biomarkers, phenotypes, personalised medicine.

Centre de recherche

Centre de recherche du CHUS

Recherche clinique

Yes

Langues parlées et écrites

Anglais, Français

Diplômes

(2022). (Master's Thesis, MSc in Experimental and Translational Therapeutics). University of Oxford.

(2021). (Post-doctorate, Clinical research fellowship in airway disease). University of Oxford.

(2019). (Post-doctorate, Residency in pulmonology). Université de Sherbrooke.

(2017). (Certificate, Microprogram of 2nd cycle : Pedagogy in Helath Sciences). Université de Sherbrooke.

(2017). (Post-doctorate, Residency in internal medicine). Université de Sherbrooke.

(2014). (Doctorate, MD). Université Laval.

Titres de compétence

Certificat de spécialiste (médecine interne) Specialist certificate (internal medicine). Collège des médecins du Québec.

Certificat de spécialiste (pneumologie) Specialist certificate (respirology). Collège des médecins du Québec.

FRCPC (médecine interne)(internal medicine). Royal College of Physicians and Surgeons of Canada (The).

FRCPC (pneumologie)(respirology). Royal College of Physicians and Surgeons of Canada (The).

Licentiate of the Medical Council of Canada. Medical Council of Canada.

Expérience académique

Assistant-professor in medicine. (2022-). Université de Sherbrooke. Canada.

Clinical research fellow; Area: severe asthma. (2019-2021). University of Oxford. United Kingdom.

Médecin résident (médecine interne puis pneumologie). (2014-2019). Université de Sherbrooke. Canada.

Stages de recherche clinique sous la supervision des Docteurs Jean-Louis Aubé et Pierre Larivée - 2 x 4 semaines Sujet : syndrome de chevauchement asthme sévère & apnée obstructive du sommeil. (2017-2018). Université de Sherbrooke. Canada.

Stage de recherche clinique sous la supervision des Docteurs Pierre Larivée et Alain Vanasse - 4 semaines Sujet : prédicteurs d’une réadmission pour exacerbation aigue de MPOC. (2016-2016). Université de Sherbrooke. Canada.

Stage de recherche clinique sous la supervision du Dr Louis-Philippe Boulet - 6 mois Sujet : santé respiratoire de l’athlète. (2011-2011). Université Laval. Canada.

Prix et distinctions

  • (2027) Chaire de recherche en santé respiratoire de l'Association Pulmonaire du Québec. Université de Sherbrooke. (Prize / Award).
  • (2027) FRQS clinical research scholar salary award (Junior 1). Fonds de recherche du Québec - Santé (FRQS). (Prize / Award).
  • (2024) Researcher of the Month. Centre de recherche du CHUS. (Honor).
  • (2012) Tableau d’honneur académique canadien (Étudiant-athlète avec >80% moyenne générale). Sport interuniversitaire canadien. (Citation).
  • 11e position (hommes), Coupe du monde FINA * 32 km de nage en eau libre - 7h51min. Traversée internationale du Lac Saint-Jean. (Distinction).
  • 2018 ATS Abstract Scholarship. American Thoracic Society. (Prize / Award).
  • 2021 ATS Abstract Scholarship. American Thoracic Society. (Prize / Award).
  • BTS winter meeting conference grant. British Thoracic Society. (Prize / Award).
  • Bourse de finaliste national. Bourses Loran. (Prize / Award).
  • Boursier local. Bourses d’Excellence du Millénaire. (Prize / Award).
  • Distinction from the University of Oxford MSc in Experimental and Translational Therapeutics. University of Oxford. (Distinction).
  • Liste d'honneur du doyen - Performance exceptionnelle et engagement envers la FMSS (10% des membres du corps professoral). Université de Sherbrooke. (Distinction).
  • Meilleure qualité scientifique de l’exposé (Journée scientifique du département de médecine). Université de Sherbrooke. (Prize / Award).
  • Mention Honorable. Harvard National Model UN (simulation des nations unies). (Honor).
  • Reconnaissance de la FMRQ pour contribution remarquable au sein de ses instances. Fédération des médecins résidents du Québec (FMRQ). (Prize / Award).
  • Reconnaissance de l’implication étudiante. Université Laval. (Citation).
  • Tableau d'honneur du doyen pour l'année 2024. Université de Sherbrooke. (Distinction).
  • Étudiant athlète & service communautaire Lauréat national (SIC) & provincial (RSEQ) Natation. Sport interuniversitaire canadien. (Prize / Award).

Financement

  • Grant. (Under Review). Co-applicant. DOSE trial: Optimal Dose of Oral Corticosteroids to Treat Asthma Exacerbations a randomized controlled Trial. Canadian Institutes of Health Research (CIHR). 2 250 000 $. (2025-2030)
  • Grant. (Awarded). Principal Investigator. Canadian Consortium for understanding the role of airway mucus occlusions in cough, COPD and asthma (CANMuc). Canadian Institutes of Health Research (CIHR). Team Grant: Lung Health. 2 000 000 $. (2024-2029)
  • Grant. (Awarded). Co-applicant. The Canadian Lung Outcomes in Users of Vaping Devices (CLOUD) Study. Canadian Institutes of Health Research (CIHR). Team Grant: Lung Health 2023-11-16. 2 000 000 $. (2024-2029)
  • Grant. (Under Review). Principal Applicant. Profiling Nitric Oxide for Therapeutic Optimisation in Eosinophilic Oesophagitis (PRODIGE) – An Observational and Translational Study. Sanofi. PATHWAYS Global Innovation Grants in Type-2 Inflammation. (2025-2028)
  • Grant. (Under Review). Principal Applicant. A randomized, double-blind, placebo-controlled study assessing the effect of dupilumab on inducing clinical remission in at-risk type-2 inflammatory asthma (HOTHOT). Sanofi-Regeneron. Investigator-initiated research. 6 525 000 $. (2025-2028)
  • Grant. (Awarded). Co-applicant. Psychometric evaluation of the McMaster Cough Severity Questionnaire: a cough severity instrument for patients with chronic cough. Canadian Institutes of Health Research (CIHR). Project Grant - Fall 2024 and Spring 2025. 575 000 $. (2025-2028)
  • Grant. (Awarded). Principal Investigator. A clinical and translational research program for personalised prediction, prevention, and management of asthma. Fonds de recherche du Québec - Santé (FRQS). Starting grant for young clinician investigators - Junior 1. 60 000 $. (2023-2027)
  • Research Chair. (Awarded). Principal Investigator. Chaire de recherche en santé respiratoire de l’Association Pulmonaire du Québec (capitalised funds, interests for research). Association Pulmonaire du Québec. Chaire de recherche en santé respiratoire. 388 800 $. (2022-2027)
  • Grant. (Awarded). Principal Applicant. Risk factors for placebo responses in the ORACLE2 patient-level meta-analysis. Fondation Québécoise en Santé Respiratoire. Early Career Investigator grants 2024-2026. 40 000 $. (2025-2026)
  • Grant. (Awarded). Principal Applicant. L’inflammométrie pour améliorer la trajectoire diagnostique dans les situations d’asthme suspecté chez l’enfant et l’adulte.. Ministère de la Santé et des Services sociaux (Québec). Propulsion Santé. 400 000 $. (2024-2026)
  • Grant. (Awarded). Principal Investigator. Quebec Respiratory Health Research Biobank -Sherbrooke site. Quebec Respiratory Health Research Network. Biobank funds. 60 000 $. (2022-2026)
  • Grant. (Awarded). Co-applicant. L’évaluation de l’efficacité de la bromotyrosine urinaire à diagnostiquer l’asthme. J.A. de Sève Foundation. Investigator-initiated research. 250 000 $. (2023-2025)
  • Grant. (Awarded). Principal Investigator. Point-of-care phenotyping responses to systemic therapies in the management asthma (PRISMA): a microbiomic substudy. bioMérieux sa (France). Investigator-initiated research. 90 000 $. (2022-2025)
  • Grant. (Awarded). Principal Investigator. Diagnostic and translational values of point-of-care blood eosinophils and exhaled nitric oxide (FeNO) in people referred by primary care for suspected asthma: a pilot study. AstraZeneca Canada Inc.. Externally Sponsored Research. 152 000 $. (2022-2025)
  • Grant. (Awarded). Principal Investigator. Phenotyping Responses to Systemic Corticosteroids in the Management Asthma Attacks (PRISMA): Clinical and Translational Correlation to Type-2 Inflammatory Biomarkers. Sanofi. Pathways Global Innovation Grant. 296 918 $. (2022-2025)
  • Grant. (Awarded). Co-applicant. Impact de la stimulation du nerf vague sur la fonction respiratoire chez les asthmatiques. Quebec Respiratory Health Research Network. Projet intersectoriel. 40 000 $. (2023-2025)
  • Grant. (Awarded). Principal Investigator. Type-2 and alarmin-mediated nitric oxide (NO)/eotaxin-3 production in the airway epithelium: start-up request for preliminary in vitro experiments. Réseau de recherche en santé respiratoire du Québec. Programme de démarrage de carrière de jeunes chercheurs avec mentorat. 25 000 $. (2024-2025)
  • Grant. (Awarded). Principal Applicant. Blood Eosinophils and Fractional Exhaled Nitric Oxide for Prediction of Asthma Attacks: Patient-Level Meta-Analysis and Risk Modelling. Academy of Medical Sciences (The). Networking Grants Round 1. 25 000 $. (2024-2025)
  • Grant. (Awarded). Principal Investigator. Étude pilote DIVE: faisabilité, performance diagnostique et valeur mécanistique des éosinophiles sanguins et de l’oxyde nitrique expiré (FeNO) en situation d’asthme suspecté par la première ligne. Association Pulmonaire du Québec. Fonds de recherche de la FQSR. 40 000 $. (2022-2024)
  • Grant. (Completed). Principal Investigator. Local startup funds. Centre de recherche du CHUS. Start-up funds. 110 000 $. (2022-2024)
  • Grant. (Completed). Principal Investigator. Point-of-care precision medicine for airways disease. Fondation du CHUS (Sherbrooke, QC). Directed donation from AstraZeneca. 40 000 $. (2022-2023)
  • Grant. (Completed). Principal Investigator. Point-of-care precision medicine for airways disease. Fondation du CHUS (Sherbrooke, QC). Directed donation from GlaxoSmithKline. 50 000 $. (2022-2023)
  • Grant. (Completed). Principal Investigator. Towards the personalised prediction, prevention, and management of asthma attacks (PRISMA): setup of a collaborative translational phenotyping asthma attack service in Sherbrooke. Fonds de recherche du Québec - Santé (FRQS). Quebec Respiratory Health Research Network - Career Start-Up and Mentorship Program for Young Invest. 25 000 $. (2022-2023)
  • Scholarship. (Completed). Principal Investigator. Scholarship for clinical research fellowship in asthma. Société des Médecins (Sherbrooke, QC). Support aux formations complémentaires. 150 000 $. (2019-2022)
  • Grant. (Completed). Principal Investigator. Type 2 Innovation Grant- Mechanisms of FeNO non-suppression. Sanofi. Type 2 Innovation Grant. 80 000 $. (2019-2021)

Publications

Articles de revue

  • Celis-Preciado, Carlos Hamou Kuijpers, Elsa Ben Ramakrishnan, Sanjay Howell, Imran Wechsler, Michael E Akuthota, Praveen Couillard, S. (2025). Applying precision medicine to the heterogeneity of asthma attacks. Chest - (-), -. (Submitted).
  • Muiser, S., Müllerova, H., Belton, L., Rusibamayila, N., Erhard, C., Agusti, A., Faner, R., D. Pavord, I., Couillard,S., lnoue, H., Price,D., Olaguibel, J. M., A.M. Kerstjens, H., van den Berge, M. (2025). Association of blood eosinophils and exhaled nitric oxide withexacerbations in patients with asthma, COPD, and asthma+COPD: the NOVELTY study. Thorax (Submitted).
  • Melhorn, J., Couillard, S. (2025). Baseline membrane thickness in asthma: where type-2inflammation meets remodeling?. American Journal of Respiratory and Critical Care Medicine (Accepted).
  • Celis-Preciado, C., Hamou Kuijpers, E. B., Kourid, M.-I., Leclerc, S., Duval, M., O Cliche, D., Vézina, F.-A., Larivée, P., Lemaire-Paquette, S., Lachapelle, P., Klein, M., Couillard, S. (2025). Biological predictors of response and effects to systemic corticosteroids in asthma attacks: PRISMA translational results. The Journal of Allergy and Clinical Immunology (Submitted).
  • Hendrik Pott; Dominic L Sykes; Jeremy Charriot; Lydia Finney; Freda Yang; Sanjay Ramakrishnan; Mustafa Abdo; Simon Couillard. (2025). Breathing Barriers: Bridging Lung Health, Research, and Awareness Gaps. Lancet Respiratory Medicine (Revision Requested).
  • Couillard, S., Lachapelle, P. (2025). De-escalation of severe asthma therapy : do we wean the biologic or the inhaler first?. Canadian Respirology Today (Accepted).
  • Gronnier Morgane; Celis-Preciado Carlos; Leclerc Simon; Lachapelle Philippe; Couillard Simon. (2025). Fraction expirée du NO (FeNO): un outil complémentaire pour le diagnostic et le traitement del'asthme. InfoRQESR (Accepted).
  • Couillard, Simon; Mailhot-Larouche, Samuel; Meulmeester, Fleur L.; Brusselle, Guy; Lachapelle, Philippe; Beasley, Richard W.; Sont, Jacob K.; Steyerberg, Ewout W.; Pavord, Ian D.; Lugogo, Njira;. (2025). Impact of Normal FEV1Without Reversibility in Asthma Trials – a Placebo Patient-Level Meta-Analysis. American Journal of Respiratory and Critical Care Medicine (Submitted).
  • Chen, Wenjia; Tran, Trung N.; Townend, John; Christoff, George C.; Tsai, Ming-Ju; Altraja, Alan; Cochrane, Belinda; Cosio, Borja G.; Sivori, Martin; Murray, Ruth B.; Makris, Michael P.; Scelo, Ghislaine; Bulathsinhala, Lakmini; Ardusso, Ledit R. F.; Franchi, María Eugenia; Máspero, Jorge; Saldarini, Fernando; Stok, Ana María; Tomaszuk, Ana Giselle; Yañez, Anahí; Emmanuel, Benjamin; Emmas, Cathy; Kostikas, Konstantinos; Menzies-Gow, Andrew N.; Stjepanovic, Neda; Bosnic-Anticevich, Sinthia Z.; Denton, Eve; Gibson, Peter G.; Hew, Mark; Jenkins, Christine; Middleton, Peter G.; Peters, Matthew J.; Upham, John W.; Brusselle, Guy G.; Louis, Renaud; Schleich, Florence; Pitrez, Paulo Márcio; Popov, Todor A.; Bergeron, Celine; Bhutani, Mohit; Chapman, Kenneth R.; Côté, Andréanne; Couillard, Simon; Dorscheid, Delbert R.; Lougheed, M. Diane; Sadatsafavi, Mohsen; Celis-Preciado, Carlos Andrés; Jiménez-Maldonado, Libardo; Rodríguez-Cáceres, Bellanid; (...); Price, David. (2025). Impact of biologic initiation on oral corticosteroid use in the International Severe Asthma Registry and the Optimum Patient Care Research Database: a pooled analysis of real-world data. The Journal of Allergy and Clinical Immunology: In Practice - (-), -. (Accepted).
  • Meulmeester, Fleur L*; Mailhot-Larouche, Samuel*; Celis-Preciado, Carlos*; Lemaire-Paquette, Samuel; Wechsler, Michael E; Ramakrishnan, Sanjay; Brusselle, Guy; Corren, Jonathan; Hardy, Jo; Diver, Sarah E; Brightling, Christopher E; Castro, Mario; Hanania, Nicola A.; Jackson, David J; Martin, Neil; Laugerud, Annette; Santoro, Emilio; Compton, Chris; Hardin, Megan E; Holweg, Cecile TJ; Allu Subhashini; Hinks, Timothy SC; Beasley, Richard W; Sont, Jacob K; Steyerberg, Ewout W; Pavord, Ian D; Couillard, Simon. (2025). Inflammatory and clinical prognostic factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. The Lancet Respiratory Medicine - (-), -. (Accepted).
  • Couillard, S., Ramakrishnan, S. (2025). In the Land of Asthma, Four Risk Factors to Rule Them All. Chest (Submitted).
  • Kourid, Mohamed-Ilias Couillard, Simon. (2025). Lunsekimig’s bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?. European Respiratory Journal - (-), -. (Accepted).
  • Masse, S* ; Delisle, T* ; St-Pierre, J* ; Vezina, FA ; Iorio-Morin, C ; Couillard, S. (2025). Neuromodulation of Dyspnea – A Literature Review. Respiratory medicine - (-), -. (Accepted).
  • Celis-Preciado, C*; Leclerc, S; Duval, M; Cliche, Dominic O; Brazeau, Lucie; Vézina, Felix-Antoine; Dussault, Marylène; Larivée, Pierre; Lemaire-Paquette, Samuel; Lévesque, Simon; Lachapelle, Philippe; Couillard, Simon. (2025). Phenotyping the Responses to Systemic Corticosteroids in the Management of Asthma Attacks (PRISMA). European Respiratory Journal - (-), -. (Accepted).
  • Sadatsafavi, Mohsen; Tran, Trung N.; Scelo, Ghislaine; Tsai, Ming-Ju; Busby, John; Emmanuel, Benjamin; Heaney, Liam G.; Jenkins, Christine; Hoyte, Flavia; Canonica, Giorgio Walter; Katial, Rohit; Heffler, Enrico; Wang, Eileen; Puggioni, Francesca; Wechsler, Michael E.; Ardusso, Ledit R. F.; Máspero, Jorge; Sivori, Martin; Emmas, Cathy; Menzies-Gow, Andrew N.; Stjepanovic, Neda; Bosnic-Anticevich, Sinthia Z.; Cochrane, Belinda; Denton, Eve; Gibson, Peter G.; Hew, Mark; Middleton, Peter G.; Peters, Matthew J.; Brusselle, Guy G.; Louis, Renaud; Schleich, Florence; Christoff, George C.; Popov, Todor A.; Bergeron, Celine; Bhutani, Mohit; Chapman, Kenneth R.; Côté, Andréanne; Couillard, Simon; Dorscheid, Delbert R.; Jiménez-Maldonado, Libardo; Solarte, Ivan; Torres-Duque, Carlos A.; Hansen, Susanne; Porsbjerg, Celeste M.; Ulrik, Charlotte Suppli; Altraja, Alan; Bourdin, Arnaud; Exarchos, Konstantinos P.; Gogali, Athena; Kostikas, Konstantinos; (...); Price, David. (2025). Prevention of cardiovascular and other systemic adverse outcomes inasthma patients treated with biologics. American Journal of Respiratory Critical Care Medicine - (-), -. (Revision Requested).
  • St-Germain, O Phan, F Celis-Preciado, C Beaudoin-Grondin, B Poulin Y Vézina, F-A Garand, G Lemaire-Paquette, G Malick, M Larivée, P Lachapelle, P Couillard, S. (2025). Real-life efficacy of type-2 targeting biologics in the withdrawal from oral corticosteroid maintenance therapy in severe asthma: a retrospective cohortstudy. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine - (-), -. (Accepted).
  • Celis-Preciado, C., Lemaire-Paquette, S., Lachapelle, P., Couillard, S. (2025). Reply to: Type 2 Inflammatory Biomarkers in asthma and COPD: what wethink we know. European Respiratory Journal (Accepted).
  • Mailhot-Larouche, S Busby, J Couillard, S. (2025). Response and remission in asthma with tezepelumab: overlapping concepts informing on type-2inflammatory-dependent treatment effects. European Respiratory Journal - (-), -. (Published).
  • Ben Hamou-Kuijpers, E., Couillard. S. (2025). Smoking Gun : When COPD Therapies Fail Current Smokers. Thorax (Accepted).
  • Burns, Paloma; Eddy, Rachel; Li, Xuan; Yang, Julia; Dhillon, Satvir; Couillard, Simon; Svenningsen, Sarah; Meza, Rafael; Leipsic, Jonathon; Afshar, Tina; Zanette, Brandon; Santyr, Giles; Counil, François-Pierre; Hernandez Cordero, Ana; Matano, Sheila; de Arruda Maluf, Giulia; Leung, Clarus; Feng, Carmen; Bal, Lydia; Dhaliwal, Harnoor,Mumuni, Adeola; Lui, Caitlyn; Drew, Heather; Rayment, Jonathan; Stickland , Michael K ; Guenette, Jordan; Samji, Hasina; Struik, Laura; Aaron, Shawn; Ho, Terence ; Lam, Stephen; Maclean, Joanna; Moraes, Theo ; Sin, Don D ; Leung, Janice;. (2025). The Canadian Lung Outcomes in Users of Vaping Devices (CLOUD) Study: Protocol for a Prospective, Observational Cohort Study. BMJ Open (Accepted).
  • Mailhot-Larouche, Samuel Lachapelle, Philippe Couillard, Simon. (2025). What sex-specific differences tells us about additive versus synergistic risk prediction in asthma. CHEST Pulmonary - (-), -. (In Press).
  • Couillard, Simon Sykes, Dominic Abdo, Mustafa Yang, Freda Ramakrishnan, Sanjay Chalmers, James Thornton, Christina. (2025). Whitepaper for a greener design, conduct, and reporting of clinical trials in respiratory medicine. European Respiratory Journal - (-), -. (Accepted).
  • St-Pierre, M Couillard, S. (2024). Acute COPD Presentations With and Without Pneumonia:To Lump or Split, That is the Question. Canadian Journal of Respiratory, Critical Care and Sleep Medicine - (-), -. (Published).
  • Florence Schleich, Désirée Larenas-Linnemann, Alan Altraja, Luis Perez-de-Llano, Konstantinos Kostikas,Mohsen Sadatsafavi, Arnaud Bourdin, Roy Alton Pleasants,Mark Hew, Wenjia Chen, Libardo Jiménez-Maldonado,Simon Couillard,Charlotte Suppli Ulrik, Adeeb A. Bulkhi,Ming-Ju Tsai,George C. Christoff, Nikolaos G. Papadopoulos,Paul E. Pfeffer,Dermot Ryan,Celine Bergeron, Mona S. Al-Ahmad, Delbert R. Dorscheid,Eileen Wang,John D. Blakey, Belinda Cochrane, Matthew J. Peters,Todor A. Popov, Carlos A. Torres-Duque, Susanne Hansen, Francesca Puggioni, Kirsty Fletton,Laila Salameh,Peter G. Middleton, Paulo Márcio Pitrez,Chin Kook Rhee, Chau-Chyun Sheu, David J. Jackson,Riyad Al-Lehebi, Mariko Siyue Koh, Bassam Mahboub, Ledit R. F. Ardusso, Athena Gogali, Giorgio Walter Canonica, Piotr Kuna, Martin Sivori,Renaud Louis,Shelley Abercromby,Giuseppe Guida,Bernt Bøgvald Aarli, Aaron Beastall,Victoria Carter, Ghislaine Scelo, John Townend,Borja G. Cosio, Pujan H. Patel, (...) , David Price. (2024). Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life. World Allergy Organization Journal - (-), -. (Accepted).
  • Celis-Preciado, Carlos* Lachapelle, Philippe Couillard, Simon. (2024). Blood eosinophils take centre stage in predicting theresponse to sublingual immunotherapy (SLIT) – a familiar twist. Thorax 79 (4), 297-298. (Published).
  • Roy, MA*; Gronnier, M*; Ramphul, M; Divall, P; Lemaire-Paquette, S; Cote, A; M Ducharme, F; A Gaillard, E; Couillard, S. (2024). Diagnostic accuracy of fractional exhaled nitric oxide (FeNO) with or without blood eosinophils in childhood, adolescent, and adult asthma: protocol for a systematic review and meta-analysis. medRxiv - (-), -. DOI. (Published).
  • Couillard S, Jackson DJ, Pavord ID, Wechsley ME. (2024). How I Do It: Choosing the right biologic for the right patient with severe asthma. Chest - (-), -. (Published).
  • Mailhot-Larouche, Samuel* Celis-Preciado, Carlos* Heaney, Liam G Couillard, S. (2024). Identifying Super-Responders: aReview of the Road to Asthma Remission. Annals of Allergy, Asthma & Immunology - (-), -. DOI. (Published).
  • Jackson D ; Couillard S ; Akuthota P; Wechsler M. (2024). Management of Uncontrolled & Severe Asthma. BMJ - (-), -. (Revision Requested).
  • Bourdin, A Brusselle, G Couillard, S Fajt, M Heaney, LG Elliot, E McDowell, PJ Menzies-Gow, A Martin, N Mitchell, PD Petousi, N Quirce, S Schleich, F Pavord, ID. (2024). Phenotyping of Severe Asthma in the Era of Broad-acting Anti-asthma Biologics. Journal of Allergy and Clinical Immunology: In Practice 12 (4), 809-823. DOI. (Published).
  • Couillard, S Jackson, D J Pavord, I D Wechsler, M E. (2024). Reply to:Differences in expert opinion on selection of initial biologics and biologic switching insevere asthma. Chest - (-), -. (Accepted).
  • Pouliot, L* Désy, L* Lemieux, S-E* Celis-Preciado, C* Lemaire-Paquette, S Duval, M Leclerc, S Vézina, F-A Lachapelle, P Couillard, S. (2024). The carbon footprint of diagnostic delays in asthma. ERJ Open - (-), -. (Accepted).
  • Desy, L* Lachapelle, P Couillard, S. (2024). The excessive carbon footprint of inhalers used in airway disease – and its remedies. Touch Respiratory 9 (1), 13-15. DOI. (Published).
  • Cantin, André Couillard, S Praud, Jean-Paul. (2024). The history of respiratory medicine in Sherbrooke, Quebec. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine - (-), -. (Accepted).
  • Farmer MJS, Couillard S, Lastra AC, Ramakrishnan S. (2024). Trailblazing Clinical Trials in Asthma, Chronic Obstructive Pulmonary Disease, Sleep Medicine, and Education and Clinical Practice in 2023. Chest 165 (1), 19-21. DOI. (Published).
  • Pavord I, Couillard S, Hoyte F, Siddiqui S, Martin, N, Menzies-Gow A, Lommatzsch M. (2024). Treat-to-target: a call for earlier targeted intervention in asthma. Journal of Allergy and Clinical Immunology : In Practice - (-), -. (Accepted).
  • Pelaia, C; Melhorn, J; Hinks, T SC; Couillard, S; Vatrella, Alessandro; Pelaia, Girolamo; Pavord, Ian D. (2024). Type 2 severe asthma: Pathophysiology and treatment with biologics. Expert Review of Respiratory Medicine - (-), -. DOI. (Published).
  • Lugogo, N Mohan, A Akukthota, P Couillard, S Rhoads, S Wechsler, M E. (2023). Are We Ready for Asthma Remission as a Clinical Outcome?. Chest 164 (4), 831-834. DOI. (Published).
  • Gupta, S Couillard, S Digby, G Tse, S Green, S Aceron, R Carlsten, C Hubick, J Penz, E. (2023). Canadian Thoracic Society Position Statement on Climate Change and Choice of Inhalers for Patients with Respiratory Disease. Canadian Journal of Respiratory, Critical Care and Sleep Medicine - (-), -. DOI. (Published).
  • Gupta, S; Couillard, S; Digby, G; Tse, SM; Green, S; Penz, E. (2023). Climate Change and Inhaler Selection in Patients with Respiratory Disease. Chest 165 (3), 503-506. (Published).
  • Couillard, S Ducharme, F Pavord, ID. (2023). Clinically accessible biomarkers to assess the modifiable risk of asthma/wheezing attacks in toddlers. The Journal of Allergy and Clinical Immunology: In Practice 11 (6), 1984-1985. DOI. (Published).
  • Blaiss, M Oppenheimer, J Corbett, M L Chipps, B Bacharier, L Bernstein, J Carr, T Chipps, B Couillard, S Forno, E Grant, T Lugogo, N May, K Schauberger, E. (2023). Consensus of an ACAAI, AAAAI, and ATS Workgroup on Definition of Clinical Remission in Asthma on Treatment. Annals of Allergy, Asthma & Immunology 131 (6), 782-785. DOI. (Published).
  • Celis-Preciado, Carlos* Lachapelle, P Couillard, S. (2023). Exhaled nitric oxide (FeNO): bridging a knowledge gap in asthma diagnosis and treatment. Clinical and Experimental Allergy 54 (8), 791-793. DOI. (Published).
  • Couillard, S Côté, A. (2023). Predicting on-biologic remission in asthma: insight from the airways. Chest 163 (6), 1341-1343. DOI. (Published).
  • Celis-Preciado, C*; Leclerc S; Duval M; Cliche, DO; Larivée, P; Lemaire-Paquette, S; Lévesque, S; Côté, A; Lachapelle, P; Couillard, S. (2023). Protocol for an Observational and Translational Study Phenotyping the Responses to Systemic Corticosteroids in the Management Asthma Attacks (PRISMA). BMJ Open Respiratory Research 10 (1), e001932. DOI. (Published).
  • Petousi, N Pavord, I Couillard, S. (2023). The Lancet COPD Commission: broader questions remain. The Lancet 401 (10338), 1569-1570. DOI. (Published).
  • Couillard S ; Petousi N ; Smigiel K ; Molfino N*. (2023). Towards a Predict and Prevent Approach in Obstructive Airways Diseases. Journal of Allergy and Clinical Immunology: In Practice 11 (3), 704-712. DOI. (Published).
  • Khalfaoui L; Symon FA; Couillard S; Hargadon B; Chaudhuri R; Bicknell S; Mansur AH; Shrimanker R; Hinks TSC: Pavord ID; Fowler S; Brown V; McGarvey LP; Heaney LG; Austin CD; Howarth PH; Arron JR; Bradding P. (2022). Airway remodelling rather than cellular infiltration characterises both type2 cytokine biomarker-high and -low severe asthma. Allergy 77 (10), 2974-2986. DOI. (Published).
  • Crossingham I* ; Richardson R ; Hinks TSC ; Spencer S ; Couillard S ; Maynard-Paquette AC ; Howell I ; Thomassen D. (2022). Biologics for chronic severe asthma: a network meta-analysis. Cochrane Database of Systematic Reviews 2022 (10), -. DOI. (Published).
  • Couillard S* ; Steyerberg EW ; Beasley R ; Pavord ID. (2022). Blood eosinophils, fractional exhaled nitric oxide, and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling. BMJ Open 12 (4), e058215. DOI. (Published).
  • Couillard S*; Laugerud A; Jabeen M; Ramakrishnan S; Melhorn J; Hinks TSC; Pavord ID. (2022). Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Thorax 77 (2), 199-202. DOI. (Published).
  • Couillard S ; Pavord ID*. (2022). Fluticasone furoate: CAPTAIN of fluticasones in type-2 inflammatory asthma. Respirology 27 (3), 184-186. DOI. (Published).
  • Couillard, S. (2022). Le tezepelumab en asthme sévère. InfoRQESR Décembre 2022 (-), 3-10. (Published).
  • Couillard S*; Shrimanker R; Lemaire-Paquette S; Hynes GM; Borg C; Connolly C; Thulborn S; Moran AM; Poole S; Morgan S; Powell T; Pavord ID; Hinks TSC. (2022). Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing. Thorax 77 (9), 933-938. DOI. (Published).
  • Couillard S ; Do W* ; Beasley R ; Hinks TSC ; Pavord ID. (2022). Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE). ERJ Open Research 8 (1), 00570. DOI. (Published).
  • Couillard S ; Pavord ID* ; Heaney LG ; Petousi N ; Hinks TSC. (2022). Sub-stratification oftype-2 high airway disease for therapeutic decision-making: a ‘bomb’ (blood eosinophils) meets ‘magnet’ (FeNO) framework. Respirology 27 (8), 573-577. DOI. (Published).
  • St-Germain O* ; Lachapelle P ; Pavord ID ; Couillard S*. (2022). Tackling ‘people remodelling’ in corticosteroid dependent asthma with type-2 targeting biologics and a formal corticosteroid weaning protocol. touchREVIEWS in Respiratory & Pulmonary Diseases 7 (2), 44-7. DOI. (Published).
  • Couillard S. (2022). The alarmin(g) effect of interleukin-5 blockade on residual eosinophil function is of clinical consequence. European Respiratory Journal 60 2200597. DOI. (Published).
  • Ramakrishnan S* ; Couillard S. (2021). Antibiotics for asthma attacks – masking uncertainty. European Respiratory Journal 58 (1), 00183. DOI. (Published).
  • Couillard S; Connolly C; Borg C; Pavord ID*. (2021). Asthma in pregnancy: An update. Obstetric Medicine 14 (3), 135-144. DOI. (Published).
  • Couillard S* ; Shrimanker R; Chaudhuri R; Mansur AH; McGarvey LP; Heaney LG; Fowler SJ; Bradding P; Pavord ID; Hinks TSC. (2021). Fractional Exhaled Nonsuppression Identifies Corticosteroid-Resistant Type-2 Signaling in SevereAsthma. Am J Respir Crit Care Med 204 (6), 731-734. DOI. (Published).
  • Couillard S; Jackson DJ; Wechsler M ; Pavord ID*. (2021). How I do it. Work-up of severe asthma. Chest 160 (6), 2019-2029. DOI. (Published).
  • Turnbull CD ; Porter BML ; Evans SB ; Smith O ; Lardner R ; Hallifax R ; Bettinson HV ; Talbot NP ; Bafadhel M ; Rahman NM ; Petousi N ; Achaiah A ; Addala D ; Banka R ; Bedawi E ; Chapman S ; Danbury H ; Couillard S ; Douglas E ; Elder P ; Fries A ; Flight W ; Fraser E ; Hardinge M ; Hinks TSC ; Ho LP ; Hoyles R ; Melhorn J ; Moore A ; Nathwani V ; Nickol A ; Park J ; Patel S ; Pavord ID ; Saunders P ; Laurenson-Schafer H ; Roxburgh F ; Sundaralingam A ; Sykes A ; Tsakok M ; Wilson R ; Wrightson JM. (2021). Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant. BMJ Open Respiratory Research 8 (1), 001044. DOI. (Published).
  • Couillard S* ; Boulet LP; Lachapelle P. (2021). The controversial role of as-needed short-acting β2-agonist monotherapy in mild asthma: a short review of current guidelines. Can J of Resp Crit Care and Sleep Medicine 5 (5), 273-275. DOI. (Published).
  • Moran AM; Ramakrishnan S; Borg CA; Connolly CM; Couillard S; Mwasuku CM; Pavord ID; Hinks TSC; Lehtimaki L*. (2020). Blood Eosinophil Depletion with Mepolizumab, Benralizumab and Prednisolone in Eosinophilic Asthma. Am J Respir Crit Care Med 202 (9), 1314-1316. DOI. (Published).
  • Vanasse A; Courteau J; Courteau M; Benigeri M; Chiu YM; Dufour I; Couillard S; Larivée P; Hudon C. (2020). Healthcare utilization after a first hospitalization for COPD: a new approach of State Sequence Analysis based on the '6W' multidimensional model of care trajectories. BMC Health Serv Res 20 (1), 177. DOI. (Published).
  • Moran AM; Ramakrishnan S; Borg CA; Connolly CM; Couillard S; Mwasuku CM; Pavord ID; Hinks TSC; Lehtimaki L. (2020). Reply to Lipworth et al.: Don't Forget about Facilitatory Effects of Corticosteroids on β 2-Adrenoceptors in Acute Asthma. Am J Respir Crit Care Med 202 (12), 1743-1744. DOI. (Published).
  • Qing L; Larivee P; Courteau J; Couillard S; Poder TG; Carrier N; Belanger M; Vanasse A*. (2019). Greater eosinophil counts at first COPD hospitalization are associated with more readmissions and fewer deaths. Int J Chron Obstruct Pulmon Dis 2019 (14), 331-341. DOI. (Published).
  • Couillard S; Bélanger M; Bouchard N*. (2019). Q fever presenting as miliary pneumonia: Case imagery and differential diagnosis. Can J of Resp Crit Care and Sleep Medicine 3 (3), 164-165. DOI. (Published).
  • Poder TG ; Carrier N ; Belanger M ; Couillard S ; Courteau J ; Larivee P; Vanasse A*. (2018). Eosinophil counts in first COPD hospitalizations: a 1-year cost analysis in Quebec. Int J Chron Obstruct Pulmon Dis 8 (13), 3065-3076. DOI. (Published).
  • Bélanger M ; Couillard S ; Courteau J ; Larivée P ; Poder TG ; Carrier N ; Girard K ; Vézina FA ; Vanasse A*. (2018). Eosinophil counts in first COPD hospitalizations: a comparison of health service utilization. Int J Chron Obstruct Pulmon Dis 2018 (13), 3045-3054. DOI. (Published).
  • Couillard S; Larivee P; Courteau J; Vanasse A*. (2017). Eosinophils in COPD Exacerbations Are Associated With Increased Readmissions. Chest 151 (2), 366-373. DOI. (Published).
  • Vanasse A* ; Courteau J ; Couillard S ; Beauchesne MF ; Larivee P. (2017). Predicting One-year Mortality After a “First” Hospitalization for Chronic Obstructive Pulmonary Disease: An Eight-Variable Assessment Score Tool. Journal of COPD 14 (5), 490-497. DOI. (Published).
  • Couillard S; Bougault V; Turmel J; Boulet LP*. (2014). Perception of bronchoconstriction following methacholine and eucapnicvoluntary hyperpnea challenges in elite athletes. Chest 145 (4), 794-802. DOI. (Published).

Livres

  • Couillard S* ; Belzile M ; Campagna C ; Vezina FA ; Laferriere-Langlois, P ; Sirois-Giguere, G. (2016). Résumé en vue du Juniorat. (1.2). Canada : Internal medicine residency program, Université de Sherbrooke. (Published).

Chapitres de livre

  • Couillard S; Pavord I*. (2022). Biological Therapies for Asthma. Laurent GJ ; Shapiro SD. Encyclopedia of Respiratory Medicine (2, 411-434). Netherlands : Elsevier. DOI. (Published).
  • Pavord, Ian; Lavoie, Gabriel; Couillard, Simon. ERS Monograph Chapter. ERS Educational Publications (108 : Asthma). (Submitted).

Articles de magazine

  • Désy, Laurence Couillard, Simon. (2023). Impact environnemental: les aérosols-doseurs au banc des accusés. Le Spécialiste.
  • Couillard, S. (2022). La famille des biologiques approuvés en asthme sévère s’élargit avec l’autorisation du tezepelumab. Info-RQESR. (Décembre).
  • Selina Wellbelove. (2022). Targeting the ‘bomb’ or the ‘magnet’: a new therapeuticframework for asthma?. The Limbic Respiratory.

Rapports

  • Couillard S ; Tanguay-Rioux X ; Grandjean-Blanchet C ; Dufour S ; Labossiere M ; Ruel-Laliberte J. (2018). The Impact of Competence by Design (CBD): Report on semi-structured interviews conducted on the 2017-2018 cohort of R1s in anesthesiology and Otolaryngology/Head and Neck Surgery in Quebec. Fédération des médecins résidents du Québec. 80 p.

Articles de conférence

  • Mona Bafadhel, Surya P. Bhatt, Simon Couillard, Celeste Porsbjerg, Nadia N. Hansel, Paramita Saha-Chaudhuri, Mena Soliman, Danen M. Cunoosamy. (2025). Association between dupilumab and repeated exacerbations of chronic obstructive pulmonary disease: BOREAS and NOTUS. ERespS 2025. (Submitted).
  • Luis A. Pérez de Llano, G. Walter Canonica, Ian D. Pavord, Simon Couillard, Celeste Porsbjerg, Guy Brusselle, Mario Castro, Arnaud Bourdin, Arman Altincatal, Jason H. Kwah, Olivier Ledanois. (2025). Baseline Characteristics Associated with Multicomponent Clinical Remission Following Dupilumab Treatment in Patients With Moderate-to-SevereAsthma. European Academy of Allergy and Clinical Immunology 2025. (Accepted).
  • G. Walter Canonica, Ian D. Pavord, Simon Couillard, Guy Brusselle, Mario Castro, Arnaud Bourdin, Arman Altincatal, Jason H. Kwah, Olivier Ledanois, Luis A. Pérez de Llano. (2025). Baseline type 2 biomarkers as predictors of multicomponent clinical remission following dupilumab treatment in patients with moderate-to-severe asthma. American College of Chest Physicians - CHEST 2025. (Submitted).
  • C. A. Celis Preciado, E. Ben Hamou Kuijpers, M. I. Kourid, S. Leclerc, M. Duval, D. Cliche, F. A. Vézina, P. Larivée, S. Lemaire-Paquette, P. Lachapelle, M. Klein, S. Couillard. (2025). Biological predictors of response to systemic corticosteroids in asthmaattacks: PRISMA translational results. European Respiratory Society Congress 2025. (Submitted).
  • Celis-Preciado, C. A., Ben Hamou Kuijpers, E., Kourid, M.-I., Leclerc, S., Duval, M., O. Cliche, D., Vézina, F.-A., Larivée, P., Lemaire-Paquette, S., Lachapelle, P., Klein, M., Couillard, S. (2025). Biological predictors of response to systemic corticosteroids in asthma attacks : PRISMA translational results. 12th Annual symposium on Cytokines in Inflammation, Ageing, CanCer and Obesity. (Submitted).
  • Luis A. Pérez de Llano, Laurent Guilleminault, G. Walter Canonica, Ian D. Pavord, Simon Couillard, Celeste Porsbjerg, Guy Brusselle, Mario Castro, Arnaud Bourdin, Arman Altincatal, Jason H. Kwah, Olivier Ledanois. (2025). Elevated Inflammatory Type 2 Biomarkers at Baseline Predict Multicomponent Clinical Remission Following Dupilumab Treatment in PatientsWith Moderate-to-Severe Asthma”. Congrès Francophone d'allergologie - CFA 2025. (Accepted).
  • Martina Budimir , Rachel Gendron , Catherine Noel , Samuel Mailhot-Larouche , Simon Couillard , Philippe Lachapelle. (2025). FractionalExhaled Nitric Oxide and Asthma Control in Moderate to Severe Asthma PatientsTreated with Omalizumab: A ¸Retrospective Cohort Study. Centre Hospitalier Universitaire de Sherbrooke (CHUS).
  • Ian D. Pavord, Mami Orimo, Dave Singh, John R. Hurst, Simon Couillard, Mona Bafadhel, Sanjay Ramakrishnan, Deborah Bauer, Ashish Bansal, Lacey B. Robinson, Mena Soliman, Jigna Heble. (2025). In patients with chronic obstructive pulmonary disease and type 2 inflammation, dupilumab improves type 2 inflammatory biomarkers. JSA 2025. (Submitted).
  • M. A. Roy; M. Gronnier; M. Ramphul; S. Lemaire-Paquette; P. Divall; J. Li; Y. He; F. Schleich; G. Louis; M. Sabbe; J. L. Lopez-Campos; A. Romero-Falcon; B. Munoz- Sanchez; F. J. Alvarez-Gutierrez; J. Mallol; V. Backer; A. Sverrild; L. Lindhardt Tonnesen; M. Lluncor Salazar; K. Kowal; A. Schneider; F. Ducharme; A. Coté; E. Gaillard; S. Couillard. (2025). Meta-analysis of exhaled nitric oxide (FeNO) with or without bloodeosinophils for asthma diagnosis in adults. European Respiratory Society Congress 2025. (Submitted).
  • Simon Couillard; Njira L. Lugogo; Tonya A. Winders; Mohit Bhutani; Laurel Bates; Erik Robinson; Alison Evans; Soram Patel; Danny Gibson; David B. Price. (2025). Modelling the impact of earlierbiologic initiation in severe asthma patients. European Respiratory Society Congress 2025. (Submitted).
  • S. Mailhot-Larouche, F. L. Meulmeester, S. Ramakrishnan, M. E. Wechsler, G. Brusselle, J. Corren, S. E. Diver, C. E. Brightling, M. Castro, N. A. Hanania, D. J. Jackson, A. Moore, P. Lachapelle, T. S. Hinks, M. Holliday, R. W. Beasley, J. K. Sont, E. W. Steyerberg, I. D. Pavord, S. Couillard. (2025). Obstructive Spirometric Index Predicts Lung Function Response to LAMA inasthma: A Post-Hoc Analysis of the CAPTAIN Trial. ERS 2025. (Submitted).
  • S. Mailhot-Larouche, F. L. Meulmeester, S. Ramakrishnan, M. E. Wechsler, G. Brusselle, J. Corren, S. E. Diver, C. E. Brightling, M. Castro, N. A. Hanania, D. J. Jackson, N. Martin, D. Clarke, M. E. Hardin, P. Lachapelle, C. T. Holweg, A. Subhashini, T. S. Hinks, M. Holliday, R. W. Beasley, J. K. Sont, E. W. Steyerberg, I. D. Pavord, S. Couillard. (2025). Obstructive Spirometric Index for Asthma Attack Risk Prediction:Analysis from the ORACLE2 Patient-Level Meta-Analysis. European Respiratory Society Congress 2025. (Submitted).
  • S. Mailhot-Larouche, C. A. Celis Preciado, S. Leclerc, M. Duval, D. O. Cliche, A. Morin, F. A. Vézina, P. Larivée, G. Brusselle, P. Lachapelle, S. Couillard. (2025). Obstructive Spirometric Index to predict response to oralcorticosteroids in asthma attacks: a post-hoc analysis of PRISMA. European Respiratory Society Congress 2025. (Submitted).
  • S. Mailhot-Larouche, J. St-Pierre, F. L. Meulmeester, S. Ramakrishnan, M. E. Wechsler, G. Brusselle, J. Corren, S. E. Driver, C. E. Brightling, M. Castro, N. A. Hanania, D. J. Jackson, N. Martin, D. Clarke, A. Moore, M. E. Hardin, C. T. Holweg, A. Subhashini, T. S. Hinks, M. Holliday, R. W. Beasley, J. K. Sont, E. W. Steyerberg, I. D. Pavord, S. Couillard. (2025). Predictors of placebo response in asthma attack rates: analysis from theORACLE2 patient-level meta-analysis. European Respiratory Society Congress 2025. (Submitted).
  • Celis-Preciado, C. A., Ben Hamou Kuijpers, E., Kourid, M.-I., Leclerc, S., Duval, M., O. Cliche, D., Vézina, F.-A., Larivée, P., Lemaire-Paquette, S., Lachapelle, P., Klein, M., Couillard, S. (2025). Prédicteurs biologiques de la réponse aux corticostéroïdes systémiques dans les crise d'asthme : Résultats translationnels de l'étude PRISMA (5 juin). 52e édition de la Journée scientifique de la FMSS 2025. (Submitted).
  • Sebastian Riemann; Fleur L Meulmeester; Samuel Mailhot-Larouche ; Sanjay ; Ramakrishnan ; Michael E Wechsler ; Jonathan Corren ; Sarah E Diver ; Christopher E Brightling ; Mario Castro ; Nicola A. Hanania ; David J Jackson ; Neil Martin ; Deborah Clarke ; Alison Moore ; Megan E Hardin ; Cecile TJ Holweg ; Subhashini Allu ; Timothy SC Hinks ; Richard W Beasley ; Jacob K Sont; Ewout W Steyerberg ; Ian D Pavord ; Guy Brusselle ; Simon Couillard. (2025). Sex differences in clinical risk factors and Type-2 biomarkers for predictingasthma attacks in the ORACLE2 patient-level meta-analysis. ERS 2025. (Submitted).
  • Joel, Samuel ML, Fleur Meulmeester, Samuel LP, Simon Couillard. (2025). Type-2 Inflammation and Lung Function Changes in the Placebo Arms of Asthma Clinical Trials: Findings from the ORACLE2 Meta-Analysis. International Congress on Academic Medicine (ICAM). (Submitted).
  • Ramakrishnan, S., Couillard, S., Pavord, I.D., Çolak, Y., Buhl, R., Deslée, G., Xia, C., Heble, J., Soliman, M. (2025). Type 2 Inflammatory Biomarkers and Lung function Improvement in Patients with Chronic Obstructive Pulmonary Disease (COPD) Receiving Placebo Therapy. COPD UK 2025 (Conference | Nottingham, 10-11 juillet). (Submitted).
  • Meulmeester FL*, Celis-Preciado C*, Ramakrishnan S, Brusselle G, Corren J, Hardy J, Diver SE, Brightling CE, Castro M, Hanania NA, Jackson DJ, Wechsler ME, Martin N, Clarke D, Laugerud A, Santoro E, Compton C, Hardin ME, CTJ, Jaumont X, Hinks TSC, Beasley RW, Sont JK, EW, Pavord ID, Couillard S. (2024). Additive prognostic value of blood eosinophils and exhaled nitric oxide (FeNO) to predict asthmaattacks in the ORACLE patient-level dataset. European Respiratory Society congress. (Submitted).
  • Celis-Preciado, C* Leclerc, S Duval, M Cliche, DO Larivée, P Lemaire-Paquette, S Lévèsque, S Côté, A Lachapelle, P Couillard, S. (2024). An Observational And Translational Pilot Study Phenotyping The Response To Systemic Corticosteroids In The Management Of Asthma Attacks (Prisma): Interim Results. Am J Respir Crit Care Med, (Published).
  • Celis-Preciado, C* Leclerc, S Duval, M Cliche, DO Larivée, P Vézina, F-A Lemaire-Paquette, S Lévèsque, S Lachapelle, P Couillard, S. (2024). An Observational and Translational Pilot Study Phenotyping the Responses to Systemic Corticosteroids in the Management AsthmaAttacks (PRISMA): interim translational results. European Respiratory Congress. (Accepted).
  • Gronnier Morgane*, Mailhot-Larouche Samuel*, Godbout Krystelle, Meulmeester Fleur L., Celis-Preciado, Carlos; Lemaire-Paquette, Samuel; Wechsler, Michael E; Ramakrishnan, Sanjay; Brusselle, Guy; Corren, Jonathan; Diver, Sarah E; Brightling, Christopher E; Castro, Mario; Hanania, Nicola A.; Jackson, David J; Martin, Neil; Laugerud, Annette; Santoro, Emilio; Compton, Chris; Hardin, Megan E; Holweg, Cecile TJ; Allu Subhashini; Hinks, Timothy SC; Beasley, Richard W; Sont, Jacob K; Steyerberg, Ewout W; Pavord, Ian D; Couillard, Simon. (2024). Biomarkers Poorly Distinguish Nasal Polyposis History in Patients Participating in Asthma Clinical Trials: Findingsfrom the ORACLE2 Patient-Level Meta-Analysis. ATS. (Submitted).
  • Jackon, DJ; Brusselle, G; Wechsler, M E; Couillard, S; Virchow, J Christian; Llanos, J-P, Roseti, S L; Martin, N; Pavord, I D. (2024). Biomarkers and phenotyping: aholistic approach to asthma treatment with tezepelumab. European Respiratory Congress. (Accepted).
  • Daniela Infantes Puno, Émilie Guay, Marie-Eve Boulay, Céline Bergeron, Shelley Abercromby, Delbert Dorscheid, Mohit Bhutani, Simon Couillard, Kenneth Chapman, Ronald Olivenstein, Shawn Aaron, Diane Lougheed, Lyle Melenka, Hara Serajeddini, Andréanne Côté. (2024). Clinical And Demographic Overview of Severe Asthma Management in Canada: Canadian SevereAsthma Registry (CSAR) Baseline Characteristics. American Thoracic Society Meeting. (Published).
  • Morgane Gronnier ; Simon Couillard. (2024). Faisabilité,performance diagnostique, et valeur mécanistique des éosinophiles sanguins etde l’oxyde nitrique expiré (FeNO) ensituation d’asthme suspecté par la première ligne. Journée de la recherche en inflammation/douleur. (Submitted).
  • Mailhot-Larouche Samuel, Meulmeester Fleur, Couillard Simon;. (2024). Identification of Interactions BetweenInflammatory Biomarkers and Other Risk Factors for Asthma Attacks: Findingsfrom the ORACLE2 Patient-Level Meta-Analysis. communication de congrès (réseau AIRS ). (Published).
  • Mailhot-Larouche Samuel, Meulmeester Fleur ; Philippe Lachapelle , Couillard Simon. (2024). Immunoglobulin E (IgE) is a BiomarkerAssociated with Asthma Attacks in Patients with Concomitant Nasal Polyposis:Analysis from the ORACLE2 Patient-Level Meta-Analysis. communication de congrès (réseau AIRS ). (Published).
  • Luis A. Pérez de Llano, G. Walter Canonica, Ian D. Pavord, Simon Couillard, Celeste Porsbjerg, Guy Brusselle, Mario Castro, Arnaud Bourdin, Arman Altincatal, Jason Kwah, Olivier Ledanois. (2024). Impact of Biologic Initiation on New-Onset ofPotentially Corticosteroid-Related Adverse Effects in Patients with SevereAsthma. American Thoracic Society (ATS) 2025 International Conference. (Submitted).
  • Ian D. Pavord, Dave Singh, John R. Hurst, Simon Couillard, Mona Bafadhel, Sanjay Ramakrishnan, Xin Lu, Ashish Bansal, Lacey B. Robinson, Mena Soliman, Jigna Heble. (2024). Impactof Dupilumab on Type 2 Inflammatory Biomarkers in Patients with COPD. American Thoracic Society meeting. (Submitted).
  • Gronnier Morgane*, Mailhot-Larouche Samuel*, Meulmeester Fleur, Couillard Simon. (2024). Inflammatory Biomarkers Show LimitedAbility to Discriminate the History of Nasal Polyposis in Asthmatic Patients: Findings from the ORACLE2 Patient-Level Meta-Analysis. Canadian Respiratory Conference. (Published).
  • Gronnier Morgane1*, Mailhot-Larouche Samuel*, Meulmeester Fleur ; Couillard Simon. (2024). Inflammatory Biomarkers Show Limited Ability to Discriminate the History of Nasal Polyposis in Asthmatic Patients:Findings from the ORACLE2 Patient-Level Meta-Analysis. communication de congrès (réseau AIRS ). (Submitted).
  • Celis-Preciado, Carlos* St-Germain, Olivier* Phan, Frédéric* Lachapelle, Philippe Larivée, P Poulin, Y Grondin-Beaudoin, B Garand, G Lemaire-Paquette, S Malick, M Couillard, S. (2024). Liberal Withdrawal From Oral Corticosteroids Maintenance Therapy After Introduction Of A Biological Agent Targeting Type 2 Inflammation In Severe Asthma. Am J Respir Crit Care Med, (Published).
  • S. Ramakrishnan Z.R. McCaw S Couillard I D Pavord P Haldar. (2024). Multiple Event-time Analysis: A New Approach For Event Based Clinical Trials In Obstructive Airway Diseases. American Thoracic Society meeting. (Published).
  • Meulmeester FL*, Celis-Preciado CA*, Ramakrishnan S, Brusselle G, Corren J, Hardy J, Diver SE, Brightling CE, Castro M, Hanania NA, Wechsler ME, Jackson DJ, Martin N, Clarke D, Laugerud A, Santoro E, Compton C, Hardin ME, Holweg CT, Jaumont X, Hinks, TS, Beasley RW, Sont JK, Steyerberg EW, Pavord D, Couillard S. (2024). Multivariable prognostic relations of asthma attack risk factors in the ORACLE patient-level dataset. European Respiratory Society congress. (Accepted).
  • Carlos Celis-Preciado, Simon Leclerc, Martine Duval, Dominic O. Cliche, Lucie Brazeau, Félix-Antoine Vézina, Marylène Dussault, Pierre Larivée, Samuel Lemaire-Paquette, Simon Lévesque, Philippe Lachapelle, Simon Couillard. (2024). Phenotyping Responses to Systemic Corticosteroids inthe Management of Asthma Attacks (PRISMA): Clinical Results. Canadadian Respiratory Conference. (Published).
  • Ben Hamou-Kuijpers Elsa, Celis-Preciado Andrés Carlos, Leclerc Simon, Duval Martine, Cliche Dominic O., Larivée Pierre, Lemaire-Paquette Samuel, Lévesque Simon, Côté Andréanne, Lachapelle Philippe, Jean-Pierre Fabrice, Couillard Simon. (2024). Phénotypagedes crises d’asthme sévères (PRISMA) : une analyse translationnelle del’interaction entre le microbiome et la réponse thérapeutique. Journées de la recherche du réseau Air, Intersectorialité, Respiratoire, et Son du Québec (AIRS). Canada,
  • Ben Hamou-Kuijpers Elsa, Celis-Preciado Andrés Carlos, Leclerc Simon, Duval Martine, Cliche Dominic O., Larivée Pierre, Lemaire-Paquette Samuel, Lévesque Simon, Côté Andréanne, Lachapelle Philippe, Jean-Pierre Fabrice, Couillard Simon. (2024). Phénotypagedes crises d’asthme sévères (PRISMA) : une analyse translationnelle del’interaction entre le microbiome et la réponse thérapeutique. Journée de la recherche en inflammation/douleur. (Submitted).
  • Carlos Celis Preciado ; Simon Leclerc ; Martine Duval ; Dominic Cliche ; Pierre Larivée ; Samuel Lemaire-Paquette ; Simon Lévesque ; Félix-AntoineVézina ; Philippe Lachapelle ; Simon Couillard. (2024). Phénotypage des réponses aux corticostéroïdes systémiques dans la prise en charge des crises d'asthme (PRISMA). Journée de l'Axe Inflammation - Douleur 2024. (Submitted).
  • S. Couillard F. L. Meulmeester* C. A. Celis-Preciado* S. Ramakrishnan G. Brusselle J. Corren J. Hardy S. E. Diver C. E. Brightling M. Castro N.A. Hanania M. E. Wechsler D. J. Jackson N. Martin D. Clarke A. Laugerud E. Santoro C. Compton M. E. Hardin C. T. J. Holweg X. Jaumont T. S.C. Hinks R. W. Beasley J. K. Sont E. W. Steyerberg I. D. Pavord. (2024). Predicting Severe Asthma Attacks With Blood Eosinophils And Exhaled Nitric Oxide (FeNO): Initial Data Analysis For The ORACLE Patient-level Meta-analysis. American Thoracic Society meeting. (Published).
  • Mailhot-Larouche Samuel, Meulmeester Fleur L., Lachapelle Philippe, Celis-Preciado Carlos, Lemaire-Paquette Samuel, Ramakrishnan Sanjay, Wechsler Michael E., Brusselle Guy, Corren Jonathan, Holliday Mark, Diver Sarah E., Brightling Christopher E., Castro Mario, Hanania Nicola A., Jackson David J., Martin Neil, Laugerud Annette, Santoro Emilio, Compton Chris, Hardin Megan E., Holweg Cecile T.J., Subhashini Allu, Hinks Timothy S.C, Beasley Richard W., Sont Jacob K., Steyerberg Ewout W., Pavord Ian D., Couillard Simon. (2024). Prognostic Interaction BetweenInflammatory and Clinical Risk Factors for Asthma Attacks: Findings from theORACLE2 Patient-Level Meta-Analysis. ATS. (Submitted).
  • Morgane Gronnier, Laurence Désy; Félix-Antoine Vézina ; Philippe Lachapelle ; François-Pierre Counil ; Martine Duval ; Samuel Lemaire-Paquette ; Lucien Coulibaly ; Catherine Hudon ; Larry Lands; Francine M. Ducharme ; Sze Man Tse ; Simon Couillard1. (2024). Propulsion Santé: FeNO and blood eosinophils to Improve the Diagnostic Pathway in Suspected Asthma Cases inChildren and Adults. Canadian Respiratory Conference. (Published).
  • Morgane Gronnier, Laurence Désy ; Félix-Antoine Vézina ; Philippe Lachapelle ; François-Pierre Counil ; Martine Duval ; Samuel Lemaire-Paquette ; Lucien Coulibaly ; Catherine Hudon ; Larry Lands ; Francine M. Ducharme ; Sze Man Tse ; Simon Couillard. (2024). Propulsion santé : L’inflammométrie pour améliorer la trajectoire diagnostique dans les situations d’asthme suspecté chez l’enfant et l’adulte. Journées de la recherche du réseau Air, Intersectorialité, Respiratoire, et Son du Québec (AIRS). (Submitted).
  • Simon Couillard, Sanjay Ramakrishnan, Ian D. Pavord, Yunus Çolak, Roland Buhl, Gaëtan Deslée, Deborah Bauer, Mena Soliman, Jigna Heble. (2024). Reduction of Exacerbations According to Type 2 Inflammatory Biomarkers With Dupilumab Treatment in Patients with Chronic Obstructive Pulmonary Disease(COPD). American Thoracic Society meeting. (Submitted).
  • Mailhot-Larouche Samuel*, St-Pierre Joël*, Meulmeester Fleur, Couillard Simon. (2024). Risk Factors of Placebo Response inAsthma Trials: Insights from the ORACLE2 Patient-Level Meta-Analysis. communication de congrès (réseau AIRS). (Submitted).
  • Melhorn, J Pelaia, C Hynes, G Petousi, N Xu, H Mahdi, M Shrimanker, R Borg, C Gamlen, E Bermejo-Sanchez, L Seymour, J Couillard, S Pavord, I Hinks, T. (2024). The Differential Effects of Inhaled and Oral Corticosteroids on Type-2 Inflammation in the Blood and Airway Compartments of Eosinophilic Asthmatics. American Thoracic Society meeting. (Published).
  • St-Pierre Joël*, Mailhot-Larouche Samuel*, Meulmeester Fleur L., Celis-Preciado Carlos Lemaire-Paquette Samuel, Ramakrishnan Sanjay, Wechsler Michael E., Brusselle Guy, Corren Jonathan, Holliday Mark, Diver Sarah E., Brightling Christopher E., Castro Mario, Hanania Nicola A., Jackson David J., Martin Neil, Laugerud Annette, Santoro Emilio, Compton Chris, Hardin Megan E., Holweg Cecile T.J., Subhashini Allu, Hinks Timothy S.C., Beasley Richard W., Sont Jacob K., Steyerberg Ewout W, Pavord Ian D., Couillard Simon. (2024). Type-2 Inflammation and Lung FunctionChanges in the Placebo Arms of Asthma Clinical Trials: Findings from theORACLE2 Meta-Analysis. ATS. (Submitted).
  • Meulmeester FL ; Celis-Preciado C ; Ramakrishnan S ; Bruselle G ; Corren J ; Hardy J ; Diver SE; Brightling CE ; Castro M ; Hanania NA ; Jackson DJ ; Wechsler ME ; Martin N ; Clarke D ; Laugerud A ; Santoro E ; Compton C ; ME ; Holweg CTJ ; Jaumont X ; Hinks TSC ; RW ; Sont JK ; Steyerberg EW; Pavord ID ; Couillard S. (2024). Type-2 biomarker elevation across asthma treatment steps in the ORACLE patient-level dataset of all-comer trials. European Respiratory Society congress. (Accepted).
  • Reed, P* Beauchesne, MF Lachapelle, P Larivée, P Couillard, S. (2023). A Rare Case of Congenital Defects in the Newborn of a Patient with Uncontrolled Asthma on Dual Omalizumab-Dupilumab Biological Therapy. American Thoracicy Society meeting. (Published).
  • Celis-Preciado, C* Leclerc, S Duval, M Cliche, DO Larivée, P Lemaire-Paquette, S Lévèsque, S Côté, A Lachapelle, P Couillard, S. (2023). An Observational and Translational Pilot Study Phenotyping the Responses to Systemic Corticosteroids in the Management Asthma Attacks (PRISMA). Journées Québécoises de Recherche en Santé Respiratoire. (Published).
  • Fortin, A* Gendron, R* Lachapelle, P LeBlanc, L Roy, V Couillard, S. (2023). Blastomycosis and Multiple Concurrent Pulmonary Infections in a Benralizumab-Treated Asthmatic. American Thoracicy Society meeting. (Published).
  • Melhorn, J Pelaia, C Hynes, G Mahdi, M Shrimanker, R Borg, C Gamlen, E Bermejo-Sanchez, L Seymour, J Couillard, S Pavord, ID Hinks, TSC. (2023). Comparing responsiveness to inhaled versus oral corticosteroid treatment highlights differential effects in blood and airway compartments in eosinophilic asthma. British Thoracic Society meeting. (Published).
  • J Melhorn, C Pelaia, G Hynes, M Mahdi, R Shrimanker, C Borg, E Gamlen, L Bermejo-Sanchez, J Seymour, S Couillard, I D Pavord, T SC Hinks. (2023). Inhaled and oral corticosteroid treatment highlights differential effects in blood and airway compartments in type-2 high asthma. British Thoracic Society Meeting. (Published).
  • Diver S, Haldar K, Khalfaoui L, Symon FA, Couillard S, Hargadon B, Chaudhuri R, Bicknell S, Mansur AH, Shrimanker R, Hinks TSC, Pavord ID, Fowler SJ, Brown V, McGarvey LP, Heaney LG, Austin CD, Howarth PH, Arron JR, Choy DF, Bradding P. (2023). Relative abundance of Haemophilus as a component of the respiratory microbiome is not associated with airway epithelial MUC5AC staining. European Respiratory Society congress. (Published).
  • St-Germain, O* Phan, F* Lachapelle, P Larivée, P Poulin, Y Beaudoin-Grondin, B Garand, G Lemaire-Paquette, S Mandy, M Celis-Preciado, C Couillard, S. (2023). Sevrage libéral du traitement d’entretien de corticostéroïdes oraux après l’introduction d’un agent biologique ciblant l’inflammation de type 2 en asthme sévère. Journées Québécoises du Réseau de Recherche en Santé Respiratoire. (Published).
  • Do W*; Beasley R; Hinks TSC; Pavord ID; Couillard S. (2022). Development of a Prototype ORACLE Web app to Predict Treatment Benefits of Type-2 Targeted Anti-inflammatory Treatment in Asthma. American Thoracic Society meeting. DOI. (Published).
  • Couillard S; Peterson S; Bengtson T; van den Berge M; Price D; Beasley R; Sadatsafavi M; Janson C; Belton L; Fageras M; Mullerova H; Pavord ID*. (2022). Prototype ORACLE Score Validation in NOVELTY: Predicted versus Observed Asthma Exacerbation Rates. American journal of respiratory and critical care medicine, DOI. (Published).
  • Couillard S ; Peterson S ; Bengtsson T, ;van den Berge M ; Price D ; Beasley R ; Sadatsafavi M ; Janson C ; Papi A ; Belton L ; Fageras M ; Mullerova H ; Pavord ID*. (2022). Risk factors for corticosteroid- and antibiotic only-treated asthma attacks in the NOVELTY cohort. European Respiratory Society congress. (Published).
  • Couillard S* ; Laugerud A; Jabeen M; Ramakrishnan S; Melorn J; Hinks T; Pavord I. (2021). A proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk scaLE (ORACLE). American Thoracic Society meeting. DOI. (Published).
  • Couillard S* ; Beasley R; Steyerberg EW; Pavord ID. (2021). Blood eosinophils, exhaled nitric oxide, and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling. Journées Québécoises de Recherche en Santé Respiratoire. (Published).
  • Couillard S*; Melhorn J; Singhania A; Horowitz D; Djukanovic C; Woelk CH; Hinks TSC. (2021). Correlation of eotaxin-3 gene expression and other IL-13-induced genes in patients with asthma. European Respiratory Society congress. DOI. (Published).
  • Couillard S* ; Melhorn J; Singhania A; Horowitz D; Djukanovic R; Woelk CH; Hinks TSC. (2021). Correlation of eotaxin-3 gene expression and other IL-13-induced genes in patients with asthma. British Thoracic Society winter meeting. A60-A61. DOI. (Published).
  • Couillard S*; Melhorn J; Singhania A; Horowitz D; Djukanovíc R; Woelk C; Hinks TSC. (2021). Correlation of eotaxin-3 gene expression and other IL-13-induced genes in patients with asthma. Journées Québécoises de Recherche en Santé Respiratoire. (Published).
  • Couillard S* ; Laugerud A; Jabeen M; Ramakrishnan R; Melhorn J; Hinks TSC; Pavord ID. (2021). Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Journées Québécoises de Recherche en Santé Respiratoire. (Published).
  • Couillard S*; Laugerud A; Jabeen M; Ramakrishnan S; Melhorn J; Hinks TSC ; Pavord ID. (2021). Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. British Thoracic Society winter meeting. A6. DOI. (Published).
  • Couillard S*; Shrimanker R; Hynes G; Connolly C: Hayman A; Thulborn S; Poole S; Chaudhuri R; Mansur AH; McGarvey LP; Heaney LG; Fowler SJ; Bradding P; Pavord I; Hinks TSC. (2021). FeNO nonsuppression identifies corticosteroid-resistant type-2 signaling in severe asthma. British Thoracic Society winter meeting. (Published).
  • Couillard S*; Shrimanker R; Hynes G; Connolly C; Haryman A; Thulborn S; Moran A; Poole S; Powell T; Chaudhuri R; Mansur AH; McGarvey LP; Heaney LG; Fowler S; Bradding P; Pavord ID; Hinks TSC. (2021). Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma. Journées Québécoises de Recherche en Santé Respiratoire. (Published).
  • Couillard S* ; Do W ; Beasley R; Laugerud A; Jabeen M; Ramakrishnan S; Melhorn J; Hinks TSC; Pavord ID. (2021). Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE). Journées Québécoises de Recherche en Santé Respiratoire. (Published).
  • Couillard S*; Shrimanker R; Hynes G; Borg C; Connolly C; Hayman A; Thulborn S; Moran A; Poole S; Powell T; Chaudhuri R; Mansur AH; McGarvey LP; Heaney LG; Fowler SJ; Bradding P; Pavord ID; Hinks TSC. (2021). Raised FeNO in optimally-treated severe asthma identifies persistent eosinophilic chemotactic pull towards the airway. European Respiratory Society congress. DOI. (Published).
  • Couillard S* ; Do W; Beasley R; Laugerud A; Jabeen M; Ramakrishnan S; Melhorn J; Hinks TSC; Pavord ID. (2021). To what extent does the prototype ORACLE scale predict treatment benefits? Predicted versus observed impact of anti-inflammatory treatments. British Thoracic Society winter meeting. DOI. (Published).
  • Oliver ME*; Poole S; Borg C; Connolly C; Pavord ID; Hinks TSC; Couillard S*. (2021). Utility of adherence checks in patients with severe asthma eligible for biologics: a single centreretrospective analysis. European Respiratory Society congress. DOI. (Published).
  • Oliver ME*; Poole S; Borg C; Connolly C; Pavord ID; Hinks TSC: Couillard S*. (2021). Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis. British Thoracic Society winter meeting. DOI. (Published).
  • Dupras-Boileaum C ; Couillard S; Gaudette E; Poulin Y. (2020). A Case of Follicular Lymphoma Presenting as Severe Interstitial Pneumonia. American Thoracic Society meeting. DOI. (Published).
  • Couillard S* ; Shrimanker R; Hynes G; Borg C; Connolly C; Harman A; Poole S; Moran A; Powell T; Pavord I; Hinks T. (2020). Mechanisms of FeNO Non-Suppression in Severe Asthma: Analysis of Sputum Type 2 Cytokines and Chemokines. European Respiratory Society congress. DOI. (Published).
  • Belanger M; Couillard S; Vezina FA; Girard K; Larivee P; Poder TG; Courteau J; Vanasse A. (2018). Blood Eosinophil levels in First Hospitalization for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Are Associated with Increased COPD-Related Readmissions. American Thoracic Society meeting. (Published).
  • Couillard S; Bélanger M; Courteau J; Larivée P; Vanasse A. (2018). Blood eosinophils, readmissions and healthcare costs in COPD: a retrospective analysis. AstraZeneca Scientific Summit – Respiratory medicine. (Published).
  • Couillard S* ; Belanger M; Bouchard N. (2018). Miliary pneumonia as a novel radiological manifestation of Q fever. American Thoracic Society meeting. (Published).
  • Tanguay-Rioux X; Grandjean-Blanchet C; Dufour S; Labossière M; Ruel-Laliberté J; Couillard S. (2018). The Impact of Competency by Design. Canadian Conference on Medical Education. (Published).
  • Tanguay-Rioux X; Grandjean-Blanchet C; Dufour S; Labossiere M; Ruel-Laliberte J; Couillard S*. (2018). The impact of Competency by Design on Quebec PGY1s in the 2017-2018cohorts in anesthesiology and ENT/HNS. International Conference on Residency Education. (Published).
  • Couillard S, Bougault V, Turmel J, Boulet LP*. (2012). Perception of bronchoconstriction in the elite athlete: relationshipwith sport, airway responsiveness and inflammation. Congrès annuel joint de l’Association des Pneumologues de la Province du Québec et du Réseau en Santé Respiratoire. DOI. (Published).

Autres contributions

Cours enseignés

  • Le microbiome dans la physiologie, l'immunologie et le métabolisme de l'hôte. MCR717. (2024-02-15 à 2024-02-15).(2CR).
  • Cells and molecules of inflammation - course on Eosinophils. IML703. (2023-03-08 à 2024-03-31).(2CR).
  • Applied Respiratory Pathophysiology. (2020-02-10 à 2021-02-10).(3CR).

Activités de collaboration internationale

  • Lead investigator. United Kingdom. Blood eosinophils, fractional exhaled nitric oxide, and the risk of asthma attacks in randomised controlled trials: systemic review and control arm patient-level meta-analysis for clinical prediction modelling.
  • Co-investigator. United Kingdom. Biomarker-stratified asthma exacerbation rates in the NOVELTY prospectiveobservational cohort and validation of the prototype Oxford Asthma attaCk risk scaLE (ORACLE).
  • Global Principal Investigator. United Kingdom.

Présentations

  • (2024). Blood eosinophils and FeNO are complementary biomarkers of the modifiable risk of asthma attacks. Meakins-Christie Research Seminar Series. Montreal, Canada
  • (2024). HOT TOPICS IN ASTHMA: Should biomarkers be used in mild-moderate asthma?. InterAsma Webinars. Italy
  • Wechsler M. (2023). "How I do it" Severe Asthma Biologic case Discusssion. Severe Asthma Medical Conference. Montréal, Canada
  • (2023). Asthme: pas besoin d'un rendez-vous pour agir. Asthme léger-modéré. Téléconférence provinciale aux médecins de famille. Canada
  • (2023). Clinical and Translational signifiance of FeNO non-suppression in asthma. CRS - CTS meeting. Montréal, Canada
  • Vézina FA. (2023). Dispositifs d'inhalation: caractéristiques et utilisation dans la pratique clinique. Conférence-midi aux pneumologues et résidents. Sherbrooke, Canada
  • (2023). Drinking the Kool-Aid in Oxford: Prédire et traduire le risque modifiable des crises d'asthme. Conférence hebdomadaire du département de médecine, Université de Sherbrooke. Sherbrooke, Canada
  • (2023). Exhaled nitric oxide, blood eosinophils, and the modifiable risk of asthma attacks. CSACI ASM. Ottawa, Canada
  • (2023). FeNO 101 pour pneumo...et le risque modifiable des crises d'asthme. Conférence-midi local des pneumologues. Trois-Rivières, Canada
  • (2023). FeNO 101...et le risque modifiable des crises d'asthme. Conférence-midi locale aux internistes. Chicoutimi, Canada
  • (2023). FeNO 101...et le risque modifiable des crises d'asthme. Conférence-midi aux pneumologues et résidents, Sacré-Coeur. Montréal, Canada
  • St-Jean M. (2023). In Practice: Wearing of OCS in severe asthma and managing the risk ok adrenal insufficiency. GSK sevrage corticos national. Téléconférence nationale aux pneumologues et allergologues. Canada
  • (2023). L'asthme précisément - conférence aux internistes. Colloque de médecine interne. sherbrooke, Canada
  • (2023). L'investigation de l'asthme sévère. Conférence-midi aux internistes. Granby, Canada
  • (2023). L'étudiant(e) MD et le programme clinicien-chercheur. Cours aux étudiants de médecine, Université de Sherbrooke. sherbrooke, Canada
  • St-Jean M. (2023). Pratico-pratique: Le sevrage des CSO en asthme sévère et insuffisance surrénalienne. GSK sevrage corticos national (téléconférence). Canada
  • (2023). Precisely severe asthma. GSK Calgary. Calgary, Canada
  • Couillard S. (2023). Prediction and Prevention of asthma attacks. World Congress of Asthma (Interasma). Canada
  • (2023). Treatable Traits. GSK late night with Richard Leigh Peter Gibson. Téléconférence nationale aux pneumologues et allergologues. Canada
  • (2023). Work-up of severe asthma. Sanofi Masterclass (Téléconférence). Norway
  • Couillard S, Pavord I. (2022). Blood eosinophils, FeNO, and the modifiable risk of asthma attacks. AstraZeneca National Speaker Tour. Calgary, Canada
  • Couillard, S Busse, W. (2022). Can a predict and prevent treatment strategy help achieve clinical remission for asthma?. European Respiratory Society (ERS) conference. Barcelona, Spain
  • Couillard S. (2022). Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing. Canadian Respiratory Research Network meeting. Ottawa, Canada
  • Couillard S. (2022). L’asthme, précisément – le programme PRISMA. GESER (groupe de recherche de l'IUCPQ). Québec, Canada
  • Couillard S. (2022). L’asthme professionnel. Conférence aux résidents et pneumologues de Sherbrooke. Sherbrooke, Canada
  • Couillard S. (2022). Measuring eosinophilic airway inflammation. TADIS 2022: Treatable Traits Initiative. United Kingdom
  • Couillard S. (2022). Oxyde nitrique expiré (FeNO) 101. Réseau Québécois d’Éducation en Santé Respiratoire - webinaire. Canada
  • Couillard S Bhutani M Chan C Côté A Dorscheid D Ducharme F Nair, P. (2022). Post-ATS National Webinar. Post-ATS National Webinar. Canada
  • Couillard S. (2022). Prédire et prévenir le remodelage bronchique et humain en asthme. Webconférence québécoise. Canada
  • (2022). Quiz et mise à jour en asthme sévère. Association des pneumologues de la province de Québec. Montréal, Canada
  • (2022). Revue de l'année 2022: Asthme sévère et inflammation de type 2 - de l'enfance à l'âge adulte. Webinaire québécoise. Canada
  • Couillard S. (2022). Revue sur les traitements de l'asthme sévère. Communauté de pratique en santé respiratoire du Réseau Québécois d’Éducation en Santé Respiratoire. Réseau Québécois d’Éducation en Santé Respiratoire - webinaire. Canada
  • Couillard S. (2022). The OxfoRd Asthma attaCk risk scaLE (ORACLE). GSK UK Scientific Workshop: Biomarkers in Severe Asthma. Londres, United Kingdom
  • Couillard S. (2022). The OxfoRd Asthma attaCk risk scaLE (ORACLE) papers. Centre of Excellence in Treatable Traits Journal Club. Newcastle, Australia
  • Couillard S, Pavord I. (2022). Type-2 inflammation as a treatable trait. Treatable Trait Symposium. Helsinki, Finland
  • Couillard S Ducharme F Côté A. (2022). Une mise-à-jour provinciale du congrès 2022 de l’American Thoracic Society (ATS) International Conference. Quebec-wide webinar. Canada
  • Couillard S. (2022). Échec et réponse partielle à la biothérapie: comment gérer la 2e ligne de traitements. Congrès Québécois en Santé Respiratoire. Montréal, Canada
  • Couillard S. (2021). Blood eosinophils, FeNO, and the modifiable risk of asthma attacks. Grupo de Rasgos Tratables y Medicini de Precisión. Bogota, Colombia
  • Cote A ; Couillard S. (2021). Débat sur l’utilisation des biomarqueurs dans la prise en charge de l’asthme sévère. Forum québécois d'échanges scientifiques en santé respiratoire, Webconférence québécoise. Sherbrooke, Canada
  • Couillard S. (2021). L’investigation de l’asthme sévère. Annual meeting of the Association des pneumologues de la province du Québec. Sherbrooke, Canada
  • Pavord I ; Russell R ; Hinks T ; Couillard S. (2021). Work-up of severe asthma. Oxford Masterclass on Difficult Asthma. Oxford, United Kingdom
  • Pavord I, Bafadhel M, Hinks TSC, Russell R, Couillard S. (2021). Work-up of severe asthma. Optimising the Management of Severe Asthma. Oxford, United Kingdom
  • Pavord I ; Hinks T ;Couillard S. (2021). Work-up of severe asthma. Oxford Masterclass on Difficult Asthma. Oxford, United Kingdom
  • Pavord I, Couillard S. (2019). Grand Rounds clinical case: aspirin exacerbated respiratory disease. Oxford Grand Rounds, Acute General Medicine. Sherbrooke, United Kingdom